Skip to content
News
Data
Podcast
Clinics
EVENTS
News
Data
Podcast
Clinics
EVENTS
Search
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Advertise
NEWSLETTER
News
Data
Podcast
Clinics
EVENTS
News
Data
Podcast
Clinics
EVENTS
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
About
Contact
About
Contact
Advertise
nEWSLETTER
Search
Search
Function, Google partner to...
Immorta Bio develops AI-des...
Phase 1b data show Rubedo L...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Function, Google partner to...
Immorta Bio develops AI-des...
Phase 1b data show Rubedo L...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
diabetic macular edema
Biotech
BioAge tests an aging pathway against eye disease
Biotech
BioAge targets aging-driven eye disease with oral therapy
Biotech
UNITY Biotech reveals topline results from senolytic DME trial
Biotech
New research supports therapeutic potential of senolytics in DME
Biotech
UNITY Biotech announces positive results from Phase 2 BEHOLD study on diabetic macular edema
Biotech
Investment
UNITY Biotech doubles share price after positive data for diabetes-related vision loss drug
The latest longevity science, investment, innovation and insight, delivered every morning.
First Name
(Required)
Email Address
(Required)
Contact Source
Unlock Longevity Biotech Report for FREE
$617BN - Annual global revenue by 2045
$30BN+ - Invested in under 2 years
3,036 - Therapeutics individually assessed
Access full report
